Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer

Journal of Clinical Oncology

Volumn 19, Issue 21, 2001, Pages 4150-4159

  Leonard, R ^a   Hardy, J ^a   Van Tienhoven, G ^a   Houston, S ^a   Simmonds, P ^a   David, M ^a   Mansi, J ^a  

^a SINGLETON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MILTEFOSINE; PLACEBO;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SKIN METASTASIS; TREATMENT FAILURE;

EID: 0035503414     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.21.4150     Document Type: Article

References (32)

1. A biostatistical study of locally recurrent breast carcinoma
2. The significance of recurrence in breast cancer
3. Frequency, anatomical distribution and management of local recurrences after definitive therapy for breast cancer
4. Prognostic indicators in patients with isolated local-regional recurrence of breast cancer
5. The implications of local recurrence of breast cancer as the first site of therapeutic failure
6. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who received adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial
7. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer
8. Récidives mammaires après traitements conservateurs des cancers du sein: Facteurs prédictifs et signification pronostique
9. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM)
10. Local recurrence after breast conservation therapy for early stage breast carcinoma: Detection, treatment, and outcome in 266 patients - Dutch Study Group on Local Recurrence after Breast Conservation (BORST)
11. Local recurrence after breast conservation surgery and radiotherapy: Frequency, time course and prognosis
12. Conventional management of breast cancer's cutaneous manifestations
13. Experimental therapeutic studies with miltefosine in rats and mice
14. Experimental pharmacology of Miltex and its constituents
15. Effects of Hexadecylphosphocholine on cellular function
16. Molecular targets of miltefosine
17. Hexadecylphosphocholine inhibits inositol phosphate and protein kinase C activity
18. Inhibitors of signal transduction: The alkylphosphocholines
19. Hexadecylphosphocholine in the topical treatment of skin metastases: A phase I trial
20. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients
21. French multicentric phase II study of topically applied miltefosine (hexadecylphosphocholine) in skin metastasized breast cancer: Preliminary results
22. Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer
23. Miltefosine 6% solution (Mil) as a local treatment in cutaneous metastases of breast cancer in patients receiving a concomitant systemic therapy: Preliminary results
24. 6% Miltefosine solution (Mil) locally used as a single palliative therapy in cutaneous metastases from breast cancer
25. Overview of the clinical development of miltefosine solution (Miltex) for the treatment of cutaneous breast cancer
26. Topical treatment of skin metastases with 6% miltefosine solution (Miltex) in patients with breast cancer: A meta-analysis of 443 patients
27. Evaluation of sample size and power for analysis of survival with allowance for non uniform patient entry, losses to follow-up, non compliance and stratification
28. Group sequential methods in the design and analysis of clinical trials
29. Psychological understanding and management of the skin cancer patient